Sodium Ferric Gluconate

Brand names: Ferrlecit
Drug class: Antineoplastic Agents

Usage of Sodium Ferric Gluconate

Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy

Treatment of iron deficiency anemia in adult and pediatric hemodialysis patients receiving epoetin alfa therapy.

In patients with chronic kidney disease (CKD) on hemodialysis, IV iron superior to orally administered iron in increasing hemoglobin concentrations and/or minimizing dosage of an erythropoiesis-stimulating agent (ESA) (e.g., epoetin alfa); the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) guidelines state that the IV route of iron administration is preferred in such patients.

Limited data suggest that iron sucrose and sodium ferric gluconate injections may be associated less frequently with serious adverse effects (e.g., hypersensitivity reactions) compared with iron dextran injection.

Safety and efficacy not established for the prevention and/or treatment of iron deficiency anemia not associated with CKD (e.g., HIV- or cancer-related anemia).

Relate drugs

How to use Sodium Ferric Gluconate

Administration

IV Administration

For solution and drug compatibility information, see Compatibility under Stability.

Administer (diluted) by slow IV infusion or (undiluted) by slow IV injection.

Dilution

For IV infusion, dilute recommended adult or pediatric dosage in 100 or 25 mL of 0.9% sodium chloride, respectively.

Use immediately after dilution.

Rate of Administration

IV infusion: slowly (e.g., over 1 hour).

IV injection (adults): slowly, up to 12.5 mg/minute at the end of dialysis.

Dosage

Dosage is expressed in terms of mg of elemental iron. Sodium ferric gluconate injection contains the equivalent of 12.5 mg of elemental iron per mL.

Pediatric Patients

Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy IV

1.5 mg/kg (up to 125 mg/dose) administered at or during hemodialysis for 8 sequential dialysis sessions.

Adults

Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy IV

125 mg administered at sequential dialysis sessions or during the dialysis session itself. Most patients will require a minimum cumulative dose of 1 g of elemental iron, administered over 8 sessions at or during sequential dialysis treatments, to achieve a favorable hemoglobin or hematocrit response.

Monitor iron indices (i.e., transferrin saturation [TSAT], serum ferritin concentrations) periodically, and use results (in conjunction with hemoglobin concentrations and ESA dosage) to guide iron therapy. Once patients achieve TSAT levels ≥20% or serum ferritin concentrations ≥100 ng/mL, continue IV iron therapy at the lowest dose necessary to maintain target hematocrit/hemoglobin levels and iron stores within acceptable limits.

Prescribing Limits

Pediatric Patients

Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy IV

Maximum dose: 125 mg per session.

Warnings

Contraindications

  • Known hypersensitivity to sodium ferric gluconate or any ingredient in the formulation.
  • Evidence of iron overload.
  • Anemias not associated with iron deficiency.

    • Warnings/Precautions

    Iron Overload

    Not easily eliminated from the body (not dialyzable) and accumulation can be toxic; avoid unwarranted therapy.

    Excess storage of iron may possibly result in a syndrome similar to hemosiderosis, particularly in patients whose anemia is not attributable to iron deficiency (e.g. those with hemoglobinopathies or other refractory anemias that might be erroneously diagnosed as iron deficiency anemia).

    Hypotension

    Possible hypotension accompanied by flushing, lightheadedness, malaise, fatigue, weakness, or severe pain in the chest, back, flanks, or groin. Such reactions are not associated with sensitivity and usually resolve within 1–2 hours. May require volume expansion if symptomatic.

    Sensitivity Reactions

    Hypersensitivity Reactions

    Potentially fatal sensitivity (e.g. anaphylactic or anaphylactoid) reactions possible; use with caution, particularly in patients with a history of allergic reactions to iron dextran.

    If serious anaphylactoid reactions occur, institute appropriate resuscitative measures.

    Specific Populations

    Pregnancy

    Category B.

    Lactation

    Not known whether sodium ferric gluconate is distributed into milk; use with caution in nursing women.

    Pediatric Use

    Safety and efficacy not established in children <6 years of age.

    Contains Benzyl Alcohol; not recommended for use in neonates.

    Geriatric Use

    Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults; use caution in dosage selection and adjustment.

    Titrate dosage carefully.

    Common Adverse Effects

    Hypotension, nausea, vomiting and/or diarrhea, pain, hypertension, allergic reaction, chest pain, pruritus, back pain.

    What other drugs will affect Sodium Ferric Gluconate

    No formal drug interaction studies to date.

    Specific Drugs

    Drug

    Interaction

    Comment

    ACE inhibitors

    Possible potentiation of adverse effects (e.g., hypotension, sensitivity reactions) associated with IV iron therapy

    Use concomitantly with caution

    Iron, oral

    Reduced absorption of oral iron

    Concomitant use not recommended

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords